7 Key Products That Could Help Dig Valeant Out of Its Hole
Valeant's CEO projects that a $1 billion portfolio of key products will help the drug maker fight debt and exclusivity challenges. Source: BioSpace
Valeant's CEO projects that a $1 billion portfolio of key products will help the drug maker fight debt and exclusivity challenges. Source: BioSpace
MabVax’s antibody-based radioimmunotherapy product MVT-1075 is currently being tested on 22 patients with CA19-9 positive malignancies in a Phase I trial. Source: BioSpace
The feud stems from a Florida-based pharmaceutical startup, Altor BioScience, which Cher invested in. Source: BioSpace
Adaptimmune is making strides on becoming a fully integrated cell therapy company behind its T Cell Receptor technology Source: BioSpace
Boragen is located in Research Triangle Park in Durham, N.C., and focuses on boron-based development of anti-bacterials and anti-fungicides for the agricultural industry. Source: BioSpace
GlaxoSmithKline CEO Emma Walmsley is eying a big acquisition to spur revenue growth but is making sure that her company will not overpay. Source: BioSpace
Dr. Erwin Erfe, head of the PAO Forensic Laboratory, said the 4 children they examined contracted dengue 6 months after receiving the vaccine. Source: BioSpace
Vivek Ramaswamy's Axovant has egg on its face after it was forced to own up to the fact it misreported mid-stage data on a drug it hoped to take into…
As an emerging leader in the field of ophthalmology, Novaliq is currently pursuing two late-stage clinical trials in the United States. Source: BioSpace
With headquarters located in San Diego, Calif. and Kalamazoo, Mich., Cirius Therapeutics is a clinical-stage pharmaceutical company focused on developing a treatment for NASH. Source: BioSpace